Mobile website
Archive > Volume 24 Issue 3 > 2017,24(3):271-277. DOI:10.3872/j.issn.1007-385X.2017.03.010 Prev Next
Clinical Research
Correlation between secretion of high-mobility group proteins and tumor-infiltrating lymphocytes in cervical carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To explore expression status of high mobility group B1 and N1 (HMGB1 and HMGN1) in cervical carcinoma cells and their relationship with tumor infiltrating lymphocytes (TILs). Methods:One hundred postoperative tumor tissue specimens from the patients with early cervical carcinoma who were hospitalized in Cancer Hospital of Tianjin Medical University during April 2012 to September 2015 were collected, among them stage Ⅰ and stage Ⅱ in each of 50 cases. Immune histochemical assay was used to detect expressions of HMGB1, HMGN1, CD3 and CD8 in the tumor tissues. According to overall staining intensity, HMGB1 and HMGN1 were divided into high expression group and low expression group respectively, and divided into cytoplasmic expression group and no cytoplasmic expression group based on expression of cytoplasm. Number of CD3+ and CD8+ cells in the tumor tissues were compared between the high expression group and the low expression group as well as between cytoplasmic expression group and no cytoplasmic expression group respectively. Results: Expression intensities of HMGB1 and HMGN1 in the tumor tissues as well as whether or not expression of HMGB1 and HMGN1 in cytoplasm all did not obviously correlate with age, FIGO staging and pathological grade (all P>0.05). Expressions of HMGB1 and HMGN1 in cytoplasm showed a positive correlation (P<0.05). Numbers of CD3+ and CD8+ cells in cytoplasm with expressions of HMGB1 and HMGN1 groups were significantly higher than those in cytoplasm without expressions of HMGB1 and HMGN1 groups (P<0.05).Conclusion: Cytoplasmic expressions of HMGB1 and HMGN1 in cervical carcinoma cells could correlate with high level of TILs in the tumor tissue, and this finding could be expected to provide a novel strategy for immunotherapy of cervical carcinoma.
Keywords:
Project Supported:
Project supported by thhe National Key Technology R&D Program (No. 2015BAI12B12), National Major Scientific and Technological Special Project for “Significant New Drugs Development” (No. 2015ZX09102018), Tianjin Major Scientific and Technological Special Project for anticancder (No. 14ZCKZSY00166), and National Natural Science Foundation of China (No. 81672697)
Clc Number:
